BR112020008664A8 - Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo - Google Patents

Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo

Info

Publication number
BR112020008664A8
BR112020008664A8 BR112020008664A BR112020008664A BR112020008664A8 BR 112020008664 A8 BR112020008664 A8 BR 112020008664A8 BR 112020008664 A BR112020008664 A BR 112020008664A BR 112020008664 A BR112020008664 A BR 112020008664A BR 112020008664 A8 BR112020008664 A8 BR 112020008664A8
Authority
BR
Brazil
Prior art keywords
applications
act
macrocyclic compound
weel inhibitor
weel
Prior art date
Application number
BR112020008664A
Other languages
English (en)
Other versions
BR112020008664A2 (pt
Inventor
Qian Wenyuan
Yang Chundao
Li Zhengwei
Li Jie
Li Jian
Chen Shuhui
Original Assignee
Shijiazhuang Sagacity New Drug Dev Co Ltd
Wuxi Biocity Biopharmaceutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Sagacity New Drug Dev Co Ltd, Wuxi Biocity Biopharmaceutics Co Ltd filed Critical Shijiazhuang Sagacity New Drug Dev Co Ltd
Publication of BR112020008664A2 publication Critical patent/BR112020008664A2/pt
Publication of BR112020008664A8 publication Critical patent/BR112020008664A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

São descritos na presente invenção um composto macrocíclico que atua como inibidor de Weel, e aplicações do mesmo no preparo de fármacos para o tratamento de doenças relacionadas a Weel. A presente invenção se refere especificamente a um composto representado pela fórmula (II), um isômero do mesmo, e um sal farmaceuticamente aceitável do mesmo.
BR112020008664A 2017-11-01 2018-10-31 Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo BR112020008664A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711058653 2017-11-01
CN201711058653.5 2017-11-01
PCT/CN2018/112909 WO2019085933A1 (zh) 2017-11-01 2018-10-31 作为Wee1抑制剂的大环类化合物及其应用

Publications (2)

Publication Number Publication Date
BR112020008664A2 BR112020008664A2 (pt) 2020-10-27
BR112020008664A8 true BR112020008664A8 (pt) 2023-01-17

Family

ID=66332843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020008664A BR112020008664A8 (pt) 2017-11-01 2018-10-31 Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo

Country Status (10)

Country Link
US (1) US11613545B2 (pt)
EP (1) EP3712150B1 (pt)
JP (1) JP7290638B2 (pt)
CN (2) CN111344290B (pt)
AU (1) AU2018361010B2 (pt)
BR (1) BR112020008664A8 (pt)
CA (1) CA3080842A1 (pt)
IL (1) IL274357B2 (pt)
SG (1) SG11202003974XA (pt)
WO (1) WO2019085933A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623615B (zh) * 2017-03-23 2022-12-13 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
EP3875460A4 (en) * 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDOPYRAZOLONE DERIVATIVE AS A WEE1 INHIBITOR AND USE OF IT
US20220220120A1 (en) * 2019-04-30 2022-07-14 Shijiazhuang Sagacity New Drug Development Co., Ltd Crystal form of wee1 inhibitor compound and use thereof
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
MX2022007624A (es) * 2019-12-20 2022-08-16 Recurium Ip Holdings Llc Combinaciones.
EP4069234A4 (en) * 2019-12-20 2024-01-03 Recurium IP Holdings, LLC ASSOCIATIONS
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
WO2023155892A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2155752B1 (en) 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
WO2009054332A1 (ja) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
PT2477628E (pt) 2009-09-15 2014-11-25 Merck Sharp & Dohme Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2013012681A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9181239B2 (en) 2011-10-20 2015-11-10 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
US9718821B2 (en) 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
CN105452246A (zh) 2013-06-06 2016-03-30 葛兰素史密斯克莱知识产权（第2号）有限公司 Zeste增强子同源物2的抑制剂
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CA3003737C (en) 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
CN108623615B (zh) * 2017-03-23 2022-12-13 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
EP3875460A4 (en) * 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDOPYRAZOLONE DERIVATIVE AS A WEE1 INHIBITOR AND USE OF IT

Also Published As

Publication number Publication date
JP2021501191A (ja) 2021-01-14
AU2018361010B2 (en) 2023-01-12
RU2020117443A3 (pt) 2021-12-01
CN117534673A (zh) 2024-02-09
CN111344290A (zh) 2020-06-26
RU2020117443A (ru) 2021-12-01
EP3712150B1 (en) 2024-06-12
US11613545B2 (en) 2023-03-28
US20200325145A1 (en) 2020-10-15
IL274357B1 (en) 2023-01-01
AU2018361010A1 (en) 2020-06-11
BR112020008664A2 (pt) 2020-10-27
EP3712150A4 (en) 2021-03-10
EP3712150A1 (en) 2020-09-23
CA3080842A1 (en) 2019-05-09
CN111344290B (zh) 2023-12-01
WO2019085933A1 (zh) 2019-05-09
IL274357A (en) 2020-06-30
IL274357B2 (en) 2023-05-01
JP7290638B2 (ja) 2023-06-13
SG11202003974XA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
CL2019002204A1 (es) Compuestos inhibidores del vih.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2019000266A1 (es) Composición de cannabis.
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
UY36123A (es) Derivados de carboxamida
UY36124A (es) Derivados de carboxamida
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD. (CN)